June 3, 2020

The Niche

Knoepfler lab stem cell blog

Month: September 2018

3 min read

Stem cells are always in the news so what’s up in the last week or two? CIRM News The dialogue over CIRM’s future is picking up a bit of steam. The San Francisco Chronicle did an in-depth piece on CIRM some weeks back and then opined that they didn’t feel supportive of another round of funding. I disagree. I think CIRM is a good future investment for California, but as a past CIRM grantee and stem cell advocate my opinion is probably not a …Read More

1 min read

Here is my initial list of 2019 Stem Cell Meetings & Conferences. Send me your listings if you don’t see your meeting here so I can start fleshing out the list more. Meeting listings are not endorsements and I try to make this list fairly comprehensive of as many stem cell meetings as I can. You can see the 2018 list of meetings as there is still time to go to some of those here. January World Stem Cell Summit, Miami, FL USA, January …Read More

3 min read

There’s a new paper in Cell Stem Cell on esophageal organoids that has really caught people’s attention. It is entitled, “3D Modeling of Esophageal Development using Human PSC-Derived Basal Progenitors Reveals a Critical Role for Notch Signaling.” It comes from a team led by Jianwen Que. Update: I didn’t realize when I first did this post that there were 2 related esophageal organoids papers in the same issue of the journal and the second one led by James M. Wells at Cincinnati Children’s has some cool …Read More

3 min read

Clinicaltrials.gov is a wonderful resource for its many users, whether a patient searching for a clinical trial to actually participate in or someone doing research as I have done, but it’s not perfect and some sponsors have been breaking the rules regarding its use. It’s a major problem in fact. Based on new draft guidance it seems that the FDA and NIH are teaming up in a big new way to punish those who are non-compliant with the Clinicaltrials.gov-related regulations and laws, including potentially …Read More

3 min read

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to take immunosuppressive drugs. I followed up with five questions for ViaCyte. Their CEO Paul Laikind sent along some answers that provide new, deeper insights. You can see a cool …Read More

3 min read

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on the news. (Update, see my new interview after the news broke with ViaCyte CEO Paul Laikind) ViaCyte has been a frequent subject of posts on The Niche related to …Read More